No Data
No Data
Incyte's Strategic Moves Amid Share Buyback and Pipeline Expansion: A Balanced Hold Rating
Incyte to Highlight Data From Its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
Incyte (Nasdaq: INCY) today announced that several abstracts featuring data from its oncology portfolio will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting held May 31 – June 4 in Chicago, and at the European Hematology Association 2024 (EHA2024) Congress held on June 13-16 in Madrid, Spain, and virtually.
Top Gap Ups and Downs on Monday: TM, BABA, STLA and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Incyte's Strategic Financial Decisions and Market Positioning: A Hold Rating Analysis
The Return of the Kitty? | Wall Street Today
Meme stock volatility hit the market Monday, sending indexes higher, but shortly before noon EST, the market boomeranged back down. Just before the closing bell, the
Incyte Buyback Seen Luring Value Investors -- Market Talk
1506 ET - Incyte's massive stock buyback is treating investors' headaches about an upcoming patent cliff. Cantor Fitzgerald analyst Eric Schmidt said in a research note last month that the cancer drug